المؤلفون: Yoshinobu Saito, Masahiko Kusumoto, Yuichiro Ohe, Masafumi Sata, Kei Sakamoto, Terufumi Kato, Toshimitsu Tokimoto, Reiko Tamura, Tomohisa Baba, Akihiko Gemma, Masatoshi Sugeno, Ou Yamaguchi, Wataru Shimizu, Masahiro Endo, Fumikazu Sakai

المصدر: Japanese Journal of Clinical Oncology

مصطلحات موضوعية: 0301 basic medicine, safety, Male, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Population, QT interval, Gastroenterology, Liver disorder, 03 medical and health sciences, 0302 clinical medicine, Japan, Internal medicine, Carcinoma, Non-Small-Cell Lung, Medicine, AcademicSubjects/MED00300, Humans, Radiology, Nuclear Medicine and imaging, Osimertinib, Lung cancer, education, Adverse effect, Protein Kinase Inhibitors, non-small cell lung cancer, Aged, education.field_of_study, Acrylamides, Aniline Compounds, business.industry, Interstitial lung disease, General Medicine, medicine.disease, Confidence interval, Progression-Free Survival, ErbB Receptors, Survival Rate, 030104 developmental biology, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, osimertinib, Mutation, Original Article, Female, business, epidermal growth factor receptor

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3b4556abdbca0ecb767d113e698aa22Test
http://europepmc.org/articles/PMC7401719Test

المؤلفون: Takashi Kasai, Ryo Arai, Masahiko Okada, Ayako Takigami, Ichiro Nakachi, Takayuki Kishikawa, Masafumi Sata, Sayo Soda

المصدر: Thoracic Cancer, Vol 11, Iss 4, Pp 935-942 (2020)
Thoracic Cancer

مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Lung Neoplasms, Tyrosine-kinase inhibitor, T790M, tyrosine kinase inhibitor, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Osimertinib, Aged, 80 and over, Aniline Compounds, General Medicine, Middle Aged, Prognosis, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, ErbB Receptors, Survival Rate, osimertinib, 030220 oncology & carcinogenesis, Female, Original Article, Adult, non‐small cell lung cancer, Pulmonary and Respiratory Medicine, medicine.medical_specialty, medicine.drug_class, Adenocarcinoma of Lung, Neutropenia, lcsh:RC254-282, 03 medical and health sciences, Internal medicine, medicine, Humans, Adverse effect, Protein Kinase Inhibitors, Aged, Retrospective Studies, Pneumonitis, Acrylamides, Proportional hazards model, business.industry, Original Articles, medicine.disease, respiratory tract diseases, Epidermal growth factor receptor T790M mutation, 030104 developmental biology, Carcinoma, Large Cell, Recurrent Non-Small Cell Lung Carcinoma, Neoplasm Recurrence, Local, business, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd21b221710ea3d5f464c5dcc42b683dTest
https://doi.org/10.1111/1759-7714.13378Test

المؤلفون: Kazushige Wakuda, Satoshi Ikeda, Masafumi Sata, Ryota Ushio, Kentaro Ito, Takashi Sato, Shigeru Tanzawa, Naoki Furuya, Makoto Nishino

المصدر: Thoracic Cancer
Thoracic Cancer, Vol 12, Iss 5, Pp 613-618 (2021)

مصطلحات موضوعية: 0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, Adult, Male, atezolizumab, non‐small cell lung cancer, medicine.medical_specialty, Lung Neoplasms, Pembrolizumab, Antibodies, Monoclonal, Humanized, lcsh:RC254-282, Cohort Studies, 03 medical and health sciences, anti‐PD‐L1, 0302 clinical medicine, Atezolizumab, Internal medicine, Carcinoma, Non-Small-Cell Lung, medicine, Humans, Lung cancer, Immune Checkpoint Inhibitors, Aged, Retrospective Studies, Aged, 80 and over, Performance status, business.industry, Anti pd 1, General Medicine, Original Articles, Middle Aged, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Confidence interval, 030104 developmental biology, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Retreatment, Female, Original Article, Nivolumab, business, Cohort study

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12194075aa42c60389387090977b3ce3Test
https://pubmed.ncbi.nlm.nih.gov/33448648Test